Ezetimibe and Statin-Associated Myopathy
Authors: Richard Fux
Journal: Annals of Internal Medicine (2004)

Letters20 April 2004Ezetimibe and Statin-Associated MyopathyRichard Fux, MD, Klaus Mörike, MD, Udo-Frank Gundel, MD, Rüdiger Hartmann, MD, and Christoph H. Gleiter, MDRichard Fux, MDFrom Tübingen, Reutlingen, and Münsingen, Germany., Klaus Mörike, MDFrom Tübingen, Reutlingen, and Münsingen, Germany., Udo-Frank Gundel, MDFrom Tübingen, Reutlingen, and Münsingen, Germany., Rüdiger Hartmann, MDFrom Tübingen, Reutlingen, and Münsingen, Germany., and Christoph H. Gleiter, MDFrom Tübingen, Reutlingen, and Münsingen, Germany.Author, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-140-8-200404200-00034 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:Background: Ezetimibe, a recently approved inhibitor of intestinal cholesterol absorption, may be added to a statin to improve control of hypercholesterolemia, although it is also licensed for monotherapy (10 mg/d). While statins carry a myotoxic potential (reported incidence, 1% to 7%), ranging from myalgia to rhabdomyolysis (1), and may also induce tendinopathy (2), ezetimibe monotherapy has not been linked with such adverse effects (3-6). However, these previous reports do not provide sufficient information about how systematically researchers searched for clinical and laboratory signs of musculoskeletal disorders.We describe 2 patients whose creatine kinase (CK) serum activities increased ...References1. Evans M, Rees A. The myotoxicity of statins. Curr Opin Lipidol. 2002;13:415-20. [PMID: 12151857] CrossrefMedlineGoogle Scholar2. Chazerain P, Hayem G, Hamza S, Best C, Ziza JM. Four cases of tendinopathy in patients on statin therapy. Joint Bone Spine. 2001;68:430-3. [PMID: 11707010] CrossrefMedlineGoogle Scholar3. Bays HE, Moore PB, Drehobl MA, Rosenblatt S, Toth PD, Dujovne CA, et al . Effectiveness and tolerability of ezetimibe in patients with primary hypercholesterolemia: pooled analysis of two phase II studies. Clin Ther. 2001;23:1209-30. [PMID: 11558859] CrossrefMedlineGoogle Scholar4. Gagne C, Gaudet D, Bruckert E. Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia. Circulation. 2002;105:2469-75. [PMID: 12034651] CrossrefMedlineGoogle Scholar5. Davidson MH, McGarry T, Bettis R, Melani L, Lipka LJ, LeBeaut AP, et al . Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia. J Am Coll Cardiol. 2002;40:2125-34. [PMID: 12505224] CrossrefMedlineGoogle Scholar6. Ballantyne CM, Houri J, Notarbartolo A, Melani L, Lipka LJ, Suresh R, et al . Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Circulation. 2003;107:2409-15. [PMID: 12719279] CrossrefMedlineGoogle Scholar7. Kosoglou T, Meyer I, Musiol B, Anderson L, Reyderman L, Statkevich P, et al . Pharmacodynamic interaction between fluvastatin and ezetimibe has favorable clinical implications [Abstract]. Atherosclerosis. 2001;2 suppl 89. Google Scholar8. Patrick JE, Kosoglou T, Stauber KL, Alton KB, Maxwell SE, Zhu Y, et al . Disposition of the selective cholesterol absorption inhibitor ezetimibe in healthy male subjects. Drug Metab Dispos. 2002;30:430-7. [PMID: 11901097] CrossrefMedlineGoogle Scholar9. Prueksaritanont T, Subramanian R, Fang X, Ma B, Qiu Y, Lin JH, et al . Glucuronidation of statins in animals and humans: a novel mechanism of statin lactonization. Drug Metab Dispos. 2002;30:505-12. [PMID: 11950779] CrossrefMedlineGoogle Scholar10. Hsiang B, Zhu Y, Wang Z, Wu Y, Sasseville V, Yang WP, et al . A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters. J Biol Chem. 1999;274:37161-8. [PMID: 10601278] CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAuthors: Richard Fux, MD; Klaus Mörike, MD; Udo-Frank Gundel, MD; Rüdiger Hartmann, MD; Christoph H. Gleiter, MDAffiliations: From Tübingen, Reutlingen, and Münsingen, Germany. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoEzetimibe and Statin-Associated Myopathy Paul S. Phillips Metrics Cited byIs it really myositis? Mimics and pitfallsZebrafish as a Model for the Study of Lipid-Lowering Drug-Induced MyopathiesSafety Considerations of Pharmacological Treatment A Pharmacogenomic Dissection of a Rosuvastatin-Induced Rhabdomyolysis Case Evokes the Polygenic Nature of Adverse Drug Reactions Expert opinion: the therapeutic challenges faced by statin intoleranceAtorvastatinEzetimibeUse of lipid-lowering medications in myasthenia gravis: A case report and literature reviewMechanisms and assessment of statin-related muscular adverse effectsDrug-Induced Disorders of the Nervous SystemMyoglobin-Associated Acute Kidney Injury in the Setting of Ciprofloxacin AdministrationUpdate on Toxic MyopathiesEzetimibe and Cholesterol AbsorptionStatin-induced myopathy: a review and updateRisk Factors and Drug Interactions Predisposing to Statin-Induced MyopathyEzetimibe-induced Relapsing Polymyositis: Table 1Drugs that affect lipid metabolismImpact of Ezetimibe on Atherosclerosis: Is the Jury Still Out?Impact of Ezetimibe on Atherosclerosis: Is the Jury Still Out?LIPID – REGULATING DRUGSToxic MyopathiesEzetimibe-related myopathy: A systematic reviewA Neuromuscular Approach to Statin-Related MyotoxicityDrug-Induced Disorders of the Nervous SystemEzetimibe-associated adverse effects: what the clinician needs to knowTransporter-mediated uptake into cellular compartmentsRabdomiolisis asociada a tratamiento combinado ezetimiba-estatinaPharmacogenetics and pharmacogenomics of cholesterol-lowering therapySafety Considerations with Gastrointestinally Active Lipid-Lowering DrugsExpert Commentary: Gastrointestinally Active Lipid-Lowering Drug SafetyMiopatía por ezetimiba reversible tras suspensión del tratamientoMyopathy Associated with Atorvastatin-Ezetimibe Combination TherapyToxic and iatrogenic myopathies44 Drugs that affect lipid metabolismNon-low-density lipoprotein cholesterol-associated actions of ezetimibe: an overviewStatin myopathy: an updateCholesterol absorption inhibitors as a therapeutic option for hypercholesterolaemiaElevation of CKP induced by ezetimibe in monotherapyCombination therapy with ezetimibe and simvastatin to achieve aggressive LDL reductionHow Safe Is Aggressive Statin Therapy?Clinical Perspectives of Statin-Induced RhabdomyolysisStatin Safety: An Overview and Assessment of the Data—2005An Assessment of Statin Safety by Muscle ExpertsReaching goal in hypercholesterolaemia: dual inhibition of cholesterol synthesis and absorption with simvastatin plus ezetimibeNew therapies for familial hypercholesterolemiaCase 4-2006Ezetimibe-associated myopathy in monotherapy and in combination with a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitorPharmacogenomics of cholesterol-lowering therapyStriated Muscle Safety of Ezetimibe/Simvastatin (Vytorin)Effect of Ezetimibe and/or Simvastatin on Coenzyme Q10 Levels in PlasmaEzetimibe/simvastatin (INEGY™) in the treatment of hyperlipidaemiaEzetimibaSupratherapeutic Response to Ezetimibe Administered with CyclosporineBekannte und weniger bekannte InteraktionenAdverse effects of statinsReplyMyopathien unter der Therapie mit LipidsenkernRationale for combination therapy with statin drugs in the treatment of dyslipidemiaEzetimibe: A novel cholesterol-lowering agent that highlights novel physiologic pathwaysEzetimibe and Statin-Associated MyopathyPaul S. Phillips, MDMontelukast-Induced Hepatitis; Dobutamine-Induced Eosinophilia; Ezetimibe and Statin-Associated Myopathy; Valproic Acid and Hypersensitivity Syndrome; Ribavirin-Induced Hemoglobinuria; Fingernail Clubbing and Discoloration Associated with Angiotensin II Receptor BlockersLipidsenkende MittelLipidsenkende MittelLipidsenkende MittelLipidsenkende Mittel 20 April 2004Volume 140, Issue 8Page: 671-672KeywordsCholesterolCreatine kinaseLaboratory testsMyalgiaPharmacokineticsPolypeptidesResearch laboratoriesRhabdomyolysisStatinsTendons ePublished: 20 April 2004 Issue Published: 20 April 2004 Copyright & PermissionsCopyright © 2004 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...